L
Leen Slaets
Researcher at European Organisation for Research and Treatment of Cancer
Publications - 41
Citations - 6519
Leen Slaets is an academic researcher from European Organisation for Research and Treatment of Cancer. The author has contributed to research in topics: Breast cancer & Cancer. The author has an hindex of 18, co-authored 39 publications receiving 4897 citations. Previous affiliations of Leen Slaets include Université libre de Bruxelles.
Papers
More filters
Journal ArticleDOI
Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis
Patricia Cortazar,Lijun Zhang,Michael Untch,Keyur Mehta,Joseph P. Costantino,Norman Wolmark,Hervé Bonnefoi,David Cameron,Luca Gianni,Pinuccia Valagussa,Sandra M. Swain,Tatiana M. Prowell,Sibylle Loibl,D. Lawrence Wickerham,Jan Bogaerts,José Baselga,Charles M. Perou,Gideon M. Blumenthal,Jens Uwe Blohmer,Eleftherios P. Mamounas,Jonas Bergh,Vladimir Semiglazov,Robert Justice,Holger Eidtmann,Soonmyung Paik,Martine Piccart,Rajeshwari Sridhara,Peter A. Fasching,Leen Slaets,Shenghui Tang,Bernd Gerber,Charles E. Geyer,Richard Pazdur,Nina Ditsch,Priya Rastogi,Wolfgang Eiermann,Gunter von Minckwitz +36 more
TL;DR: In this paper, the authors compared the three most commonly used definitions of pathological complete response (ypT0 ypN0, ypT0/is ypNs0, and ypTsN0/IsYPN0) for their association with EFS and overall survival in clinical trials of neoadjuvant treatment of breast cancer.
Journal ArticleDOI
70-Gene Signature as an Aid to Treatment Decisions in Early-Stage Breast Cancer
Fatima Cardoso,Laura J. van't Veer,Jan Bogaerts,Leen Slaets,Giuseppe Viale,Suzette Delaloge,Jean-Yves Pierga,Etienne Brain,Sylvain Causeret,Mauro Delorenzi,Annuska M. Glas,Vassilis Golfinopoulos,Theodora Goulioti,Susan J. Knox,Erika Matos,Bart Meulemans,Peter A. Neijenhuis,Ulrike Nitz,Rodolfo Passalacqua,Peter M. Ravdin,Isabel T. Rubio,Mahasti Saghatchian,Tineke J. Smilde,Christos Sotiriou,Lisette Stork,Carolyn Straehle,Geraldine A. Thomas,Alastair M. Thompson,Jacobus J.M. van der Hoeven,Peter Vuylsteke,René Bernards,Konstantinos Tryfonidis,Emiel J. Th. Rutgers,Martine Piccart +33 more
TL;DR: Among women with early-stage breast cancer who were at high clinical risk and low genomic risk for recurrence, the receipt of no chemotherapy on the basis of the 70-gene signature led to a 5-year rate of survival without distant metastasis that was 1.5 percentage points lower than the rate with chemotherapy.
Journal ArticleDOI
Radiotherapy or surgery of the axilla after a positive sentinel node in breast cancer (EORTC 10981-22023 AMAROS): a randomised, multicentre, open-label, phase 3 non-inferiority trial
M. Donker,Geertjan van Tienhoven,Marieke E. Straver,P. Meijnen,Cornelis J.H. van de Velde,Robert E. Mansel,Luigi Cataliotti,A. Helen Westenberg,Jean H. G. Klinkenbijl,Lorenzo Orzalesi,Willem H. Bouma,Huub van der Mijle,Grard A. P. Nieuwenhuijzen,Sanne C. Veltkamp,Leen Slaets,Nicole Duez,Peter W. de Graaf,Thijs van Dalen,A. Marinelli,Herman Rijna,Marko Snoj,Nigel J Bundred,Jos W. S. Merkus,Yazid Belkacemi,Patrick Petignat,Dominic A.X. Schinagl,Corneel Coens,Carlo Messina,Jan Bogaerts,Emiel J. Th. Rutgers +29 more
TL;DR: The AMAROS trial as discussed by the authors evaluated axillary lymph node dissection and axillary radiotherapy for T1-2 primary breast cancer and no palpable lymphadenopathy patients with positive sentinel nodes.
Journal ArticleDOI
Feasibility of a prospective, randomised, open-label, international multicentre, phase III, non-inferiority trial to assess the safety of active surveillance for low risk ductal carcinoma in situ - The LORD study
Lotte E. Elshof,Konstantinos Tryfonidis,Leen Slaets,A. Elise van Leeuwen-Stok,Victoria P Skinner,Nicolas Dif,Ruud M. Pijnappel,N. Bijker,Emiel J. Th. Rutgers,Jelle Wesseling +9 more
TL;DR: The LORD study aims to evaluate the safety of active surveillance in women with low-risk DCIS to explore interest in and feasibility of this randomised, international multicentre, open-label, phase III non-inferiority trial.
Journal ArticleDOI
Characterization of male breast cancer: Results of the EORTC 10085/TBCRC/BIG/NABCG International Male Breast Cancer Program
Fatima Cardoso,Fatima Cardoso,John M. S. Bartlett,John M. S. Bartlett,Leen Slaets,C.H.M. van Deurzen,C.H.M. van Deurzen,E van Leeuwen-Stok,Peggy L. Porter,Peggy L. Porter,B. Linderholm,B. Linderholm,Ingrid Hedenfalk,Carolien P. Schröder,Carolien P. Schröder,John W.M. Martens,John W.M. Martens,Jane Bayani,C. J. van Asperen,C. J. van Asperen,Melissa Murray,Clifford A. Hudis,Clifford A. Hudis,Lavinia P. Middleton,Joanna Vermeij,Kevin Punie,Judith Fraser,M Nowaczyk,Isabel T. Rubio,Stefan Aebi,Catherine M. Kelly,Kathryn J. Ruddy,Eric P. Winer,Cecilia Nilsson,L. Dal Lago,Larissa A. Korde,Kim Benstead,Oliver Bogler,Theodora Goulioti,Aleksandra Peric,Saskia Litière,K Aalders,C. Poncet,Konstantinos Tryfonidis,Sharon H. Giordano +44 more
TL;DR: Better overall (OS) and recurrence-free survival (RFS) and a significant improvement over time was observed in age-corrected BC mortality and there was no association between OS/RFS and HER-2 status, Ki67, IHC subtypes nor grade.